Summary by Moomoo AI
On March 7, 2024, Tonix Pharmaceuticals Holding Corp. announced the publication of a research paper in Psychiatry Research, detailing a Phase 3 trial of TNX-102 SL, a sublingual formulation of cyclobenzaprine, for the treatment of military-related posttraumatic stress disorder (PTSD). The study showed that TNX-102 SL is well-tolerated and demonstrated nominal improvement in PTSD severity and sleep quality within the first four weeks. These findings support the potential use of TNX-102 SL as a short-term treatment immediately following traumatic events. Additionally, the paper supports the upcoming Department of Defense-funded Phase 2 OASIS trial, which will evaluate the effects of TNX-102 SL on acute stress reaction and the prevention of PTSD after civilian motor vehicle collisions. The OASIS trial is expected to begin enrollment in the second quarter of 2024. Tonix also plans to submit a New Drug Application for TNX-102 SL, branded as Tonmya, for the management of fibromyalgia in the second half of 2024.